Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody

Sivolapenko, Gregory; Douli, V; Sirmalis, G; Merkouri, E; Κωνσταντινίδης, Κωνσταντίνος; Pectasides, Dimitrios; Skarlos, D.; Courtenay-Luck, N.; Epenetos, Agamemnon A.; Hussain, Rabia; Cook, Joel D.

doi:10.1016/s0140-6736(95)92839-1

Cited by 44 publications

(32 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, the use of small peptides instead may eliminate these shortcomings because peptide ligands are nonimmunogenic and have high affinity and selectivity for receptors. In this study, we used a synthetic peptide, designated EPPT1 (YCAREPPTRTFAYWG), derived from the CDR3 V h region of a monoclonal antibody (ASM2) raised against human epithelial cancer cells (25,31). Analysis of peptide structure revealed a ␤-strand type conformation as the active binding site (32).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe

Moore

Medarova²,

Potthast³

et al. 2004

Cancer Research

217

174

View full text Add to dashboard Cite

One of the most difficult challenges of oncology is to improve methods for early tumor detection, which is crucial for the success of cancer therapy and greatly improves the survival rate. Underglycosylated mucin-1 antigen (uMUC-1) is one of the early hallmarks of tumorigenesis and is overexpressed and underglycosylated on almost all human epithelial cell adenocarcinomas as well as in nonepithelial cancer cell lines, as well as in hematological malignancies such as multiple myeloma, and some B-cell non-Hodgkin lymphomas. In this study, we designed, synthesized, and tested a novel multimodal imaging probe specifically recognizing in vivo uMUC-1 antigen in an animal model of human cancer. Furthermore, in vivo magnetic resonanceand near-infrared-imaging experiments on tumor-bearing animals showed specific accumulation of the probe in uMUC-1-positive tumors and virtually no signal in control tumors. We expect that this probe has a potential to greatly aid in screening prospective patients for early cancer detection and in monitoring the efficacy of drug therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

“…1A). In a previous study, the EPPT1 peptide, labeled with ( 99m Tc), was used to image breast carcinomas in vivo (31).…”

Section: Introductionmentioning

confidence: 99%

In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe

Moore

Medarova²,

Potthast³

et al. 2004

Cancer Research

217

174

View full text Add to dashboard Cite

show abstract

“…consequently, the use of small peptides instead of antibodies or antibody fragments may eliminate these shortcomings, because peptide ligands are nonimmunogenic and combine high affinity and selectivity for receptors with more desirable pharmacokinetic properties. in our studies we have traditionally used a synthetic peptide, ePPt1 (YcARePPtRtFAYWG), derived from the cDR3 V h region of a monoclonal antibody (ASM2) raised against human epithelial cancer cells (30,84). Analysis of the peptide structure revealed a b-strand type portion of the sequence as the active binding site (31).…”

Section: Imaging Target-umuc-1 Tumor Antigenmentioning

confidence: 99%

“…that property of the APDtRP sequence is the basis for its exclusive immunogenicity in the underglycosylated mucin-1 protein (17). in a previous study, the ePPt1 peptide, labeled with ( 99m tc), was used to image breast carcinomas in vivo (84). the 99m tc -labeled ePPt1 peptide is the basis for a commercially developed breast cancer imaging agent.…”

Section: Imaging Target-umuc-1 Tumor Antigenmentioning

confidence: 99%

Noninvasive Imaging of Breast Cancer

Medarova

2009

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

“…Moreover, a hydrophilic conjugate with predominant kidney excretion has to be prepared. High kidney retention of the peptides and antibody fragments -labelled with a metallic radionuclide -appeared to be one of the main obstacles in the potential use of small molecules in internal radiotherapy [3]. Therefore, we have developed a new chelator somatostatin analogue which can be labelled stably with the diagnostic radionuclide 111In and its therapeutic chemical analogue 90y.…”

Section: Introductionmentioning

confidence: 99%

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

et al. 1997

View full text Add to dashboard Cite

Abstract. This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the [3-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTA-TOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1.9-fold lower with IllIn-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours. Key words':

show abstract

Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumour antibody

Cited by 44 publications

References 11 publications

In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe

In Vivo Targeting of Underglycosylated MUC-1 Tumor Antigen Using a Multimodal Imaging Probe

Noninvasive Imaging of Breast Cancer

DOTATOC: A powerful new tool for receptor-mediated radionuclide therapy

Contact Info

Product

Resources

About